Secondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort study

Hdl Handle:
http://hdl.handle.net/10144/619248
Title:
Secondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort study
Authors:
Diro, Ermias; Griensven, Johan van; Woldegebreal, Teklu; Belew, Zewdu; Taye, Melese; Yifru, Sisay; Davidson, Robert N.; Balasegaram, Manica; Lynen, Lut; Boelaert, Marleen
Abstract:
2.1 OBJECTIVES 2.1.1 General objective: To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients that have documented parasite clearance after VL treatment when used for prevention of VL relapse. 2.1.2 Specific objectives of the primary study period 2.1.2.1 Primary objectives In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the effectiveness of PSP in terms of preventing relapse and death; - to assess the safety of PSP in terms of drug-related serious adverse events or permanent drug discontinuations due to adverse events; - to assess the feasibility of PSP in terms of number of patients compliant to therapy during the first year of monthly PM secondary prophylaxis. 2.1.2.2 Secondary objectives; In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the safety of PSP in terms of: - drug-related non-serious adverse events - serious adverse events (drug-related or not) - to assess the feasibility of PSP in terms of: - number of treatment interruptions/discontinuations, - number of therapeutic interventions needed to treat adverse drug reactions
Affiliation:
MSF-OCA
Issue Date:
Jul-2018
URI:
http://hdl.handle.net/10144/619248
Type:
Other
Language:
en
Description:
Research Protocol
Appears in Collections:
MSF Research Protocols

Full metadata record

DC FieldValue Language
dc.contributor.authorDiro, Ermiasen
dc.contributor.authorGriensven, Johan vanen
dc.contributor.authorWoldegebreal, Tekluen
dc.contributor.authorBelew, Zewduen
dc.contributor.authorTaye, Meleseen
dc.contributor.authorYifru, Sisayen
dc.contributor.authorDavidson, Robert N.en
dc.contributor.authorBalasegaram, Manicaen
dc.contributor.authorLynen, Luten
dc.contributor.authorBoelaert, Marleenen
dc.date.accessioned2018-07-31T13:52:05Z-
dc.date.available2018-07-31T13:52:05Z-
dc.date.issued2018-07-
dc.identifier.urihttp://hdl.handle.net/10144/619248-
dc.descriptionResearch Protocolen
dc.description.abstract2.1 OBJECTIVES 2.1.1 General objective: To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients that have documented parasite clearance after VL treatment when used for prevention of VL relapse. 2.1.2 Specific objectives of the primary study period 2.1.2.1 Primary objectives In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the effectiveness of PSP in terms of preventing relapse and death; - to assess the safety of PSP in terms of drug-related serious adverse events or permanent drug discontinuations due to adverse events; - to assess the feasibility of PSP in terms of number of patients compliant to therapy during the first year of monthly PM secondary prophylaxis. 2.1.2.2 Secondary objectives; In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the safety of PSP in terms of: - drug-related non-serious adverse events - serious adverse events (drug-related or not) - to assess the feasibility of PSP in terms of: - number of treatment interruptions/discontinuations, - number of therapeutic interventions needed to treat adverse drug reactionsen
dc.language.isoenen
dc.rightsThese materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.pngen
dc.subjectSecondary prophylaxisen
dc.subjectvisceral leishmaniasis relapsesen
dc.subjectHIVen
dc.subjectpentamidineen
dc.subjectprophylactic agenten
dc.subjectcohort studyen
dc.titleSecondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort studyen
dc.typeOtheren
dc.contributor.departmentMSF-OCAen
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.